Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Conditions
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 668
- Registration Number
- NCT04102098
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, China
🇨🇳Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, China
🇨🇳The First Affiliate Hospital of Guangxi Medical University, Nanning, China
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 246
- Registration Number
- NCT04090411
- Locations
- 🇺🇸
Dothan Surgery Center, Dothan, Alabama, United States
🇺🇸Investigational Drug Services, Philadelphia, Pennsylvania, United States
🇺🇸Flowers Hospital, Dothan, Alabama, United States
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT04091217
- Locations
- 🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou City, China
🇨🇳Beijing Cancer Center; Renal Cancer And Melanoma Department., Beijing City, China
🇨🇳Zhejiang Cancer Hospital, Zhejiang, China
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 498
- Registration Number
- NCT04077723
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇪UZ Gent, Gent, Belgium
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04075266
- Locations
- 🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Colorado Denver Childrens Hospital Rocky Mountain MS Center, Aurora, Colorado, United States
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04060862
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇨🇦Hopital du Saint Sacrement, Quebec City, Quebec, Canada
🇺🇸Dana-Farber Cancer Institute; GYN Oncology, Boston, Massachusetts, United States
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT04049578
- Locations
- 🇺🇸
Red Oak Psychiatry Associates, PA, Houston, Texas, United States
🇺🇸Richmond Behavioral Associates, Staten Island, New York, United States
🇺🇸University Hospitals Cleveland Medical Center; Division of Child and Adolescent Psychiatry, Cleveland, Ohio, United States
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT04035005
- Locations
- 🇵🇱
Galen Clinic, Lublin, Poland
🇺🇸HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸Multiple Sclerosis Center of California, Newport Beach, California, United States
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT04034056
- Locations
- 🇮🇹
Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpigh, Bologna, Emilia-Romagna, Italy
🇮🇹Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine, Friuli-Venezia Giulia, Italy
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT04029688
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
🇺🇸Arnold Palmer Hosp-Children, Orlando, Florida, United States